News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Idera Pharmaceuticals, Inc. Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors
June 16, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today provided an update on its drug candidate pipeline targeted to Toll-like Receptors (TLRs) during its 2009 Annual Meeting of Stockholders.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Phase 2
MORE ON THIS TOPIC
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
September 24, 2026
·
2 min read
·
Gabrielle Masson
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
September 24, 2026
·
2 min read
·
Annalee Armstrong
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
IN PARTNERSHIP WITH CURIUM
How radioligand therapy is rewriting cancer care
September 24, 2026
·
1 min read
·
Jennifer C. Smith-Parker
